Tandem Diabetes Care has reported FDA clearance for a tubeless option for Tandem Mobi. A new cartridge and infusion set convert the existing pump into a wearable tubeless system.
Tubed use remains possible. The manufacturer describes up to seven days of wear with Control-IQ+ automated insulin delivery. Full US commercial launch is planned for the first half of 2027. Existing Mobi pumps are compatible, and in-warranty customers do not need a replacement pump, according to the company.
Context and evidence
The sets and cartridges are planned for pharmacy-only access for people with applicable insurance benefits. This concerns both hardware and a defined access channel. The planned launch date is separate from the clearance already granted; the source contains no independent head-to-head comparison with other tubeless systems.
What it means
The option adds a new wear configuration to an existing platform. Actual access will depend on launch, insurance benefits and medical suitability, not clearance alone.
Primary source: Original announcement. This report is based on company statements, not an independent clinical assessment.